Tricidia is a Biopharmaceutical firm that focuses on the discovery and development of therapeutics used to address renal, metabolic, and cardiovascular diseases. The stock sold off 38% recently as the FDA phase III clinical trial for its drug VALOR is nearing its end. The results of the trial and effectiveness of the drug are yet to be determined. TCDA has no revenue currently and hopes are on the success of VALOR. They have approximately $100mm of cash and marketable securities on their balance sheet and are burning through about $25mm per quarter in R\&D and Operating Expenses. As such they can likely continue to operate for a year on the current cash. The option markets are extremely pumped up with Implied Volatilities in the November at the money options currently around 400% ! Choose a side and decide if you want to buy or sell the TCDA November 7.5 - 10 Strangle (7.5 Put and 10 Call). Graph the Payoff Diagram of your chosen strategy and be sure to include the Max Gain, Max Loss, and Breakeven levels. We'll see how it pans out on November 18th